A Phase 2 interventional study of ARV-471 and Anastrozole in Breast Cancer, sponsored by Arvinas Inc.. Completed at 49 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by Arvinas Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing vepdegestrant in Breast Neoplasms — 1 open to participants now, 6 under way, 2 of them phase 3. vepdegestrant · Breast Neoplasms.
Among the 12 studies testing vepdegestrant in Breast Neoplasms, this one is the 4th largest by enrollment, is one of 6 that started in 2023, is one of 2 in phase 2, and was the 6th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →1 of the 12 studies testing vepdegestrant in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:
QuantumLeap Healthcare Collaborative · Sites in United States
Ages 18+
By country, each count listing its studies:
vepdegestrant: first FDA approval 2026 (VEPPANU). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, vepdegestrant is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 2
First in 2010; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 152 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 48 across the 12 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 12 have an industry lead sponsor. The 4 most frequent:
Arvinas Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Arvinas Inc. has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing vepdegestrant in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT05548127PfizerTACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | 2027-03-24 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing vepdegestrant in Breast Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with estrogen receptor positive/ human epidermal growth factor receptor 2 (ER+/HER2)- localized breast cancer.
This is a Phase 2, open-label, randomized, non-comparative proof of concept study of ARV-471 or anastrozole in participants with ER+/HER2- breast cancer amenable to definitive surgical resection. The main goal of this study is to evaluate the biological activity of ARV-471 and anastrozole, respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
or cytologically confirmed ER+ and - breast cancer (per local assessment). ER and HER2 status must be documented:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200 mg ARV-471 (2\*100 mg tablets) once daily for approximately 5.5 months prior to undergoing surgical resection (no later than Cycle 6 Day 18 \[C6D18\] + 14 days).
Drug: ARV-471 · Procedure: Surgical resection of breast tumor
Participants received 1 mg Anastrozole tablet orally once daily for approximately 5.5 months prior to undergoing surgical resection (no later than C6D18 + 14 days).
Drug: Anastrozole · Procedure: Surgical resection of breast tumor
100 mg tablet
Also known as: Vepdegestrant, PF-07850327
1 mg tablet
Also known as: Arimidex
Surgical resection approximately 5.5 months after starting treatment (C6D18 ± 14 days)
Percent Reduction in Ki-67 Expression From Baseline to Day 15 in Tumor Biopsies
Tumor biopsy Ki-67 expression (% of tumor cells that are positive for Ki-67) at baseline and Cycle 1 Day 15 (C1D15) was collected. Ki-67 expression was assessed by immunohistochemical staining in a central laboratory. The log-transformed Ki-67 after approximately 2 weeks of treatment as a percentage of the baseline value, ie, the ratio between the Ki-67 measurements obtained from C1D15 visit and baseline was modelled using a generalized linear model (GLM) with both stratification factors (ie, baseline Ki-67 score and the tumor size) and treatment as co-variates. The treatment effects were back transformed into geometric means and their Confidence Intervals. The percent change, in other words, relative reduction, of Ki-67 after 2 weeks of treatment is reported as the complement of the ratio between the Ki-67 measurement from C1D15 and baseline, that is 100% × (1 - geometric mean ratio between Ki-67 at C1D15 and Ki-67 at baseline).
Time frame: Baseline (during screening, prior to Day 1) and Day 15
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Study Drug Discontinuation
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE is an AE that emerges or worsens on/after the first dose of ARV-471/Anastrozole to 30 days after the last administration of the study intervention (ie, study drug treatment or surgical resection, whichever occurs last).
Time frame: From signing of consent to minimum of 30 days after last administration of study drug (up to approximately 6.5 months)
Pathologic Stage at the Time of Surgical Resection
Local pathological assessment of the tissue from surgical resection (performed after approximately 5.5 months of treatment), at minimum, included pathologic stage (ypT and ypN stage) as described in the Laboratory Manual. Participants were analysed based on the current American Joint Committee on Cancer (AJCC) staging system as follows: * Pathologic Tumor - post-neoadjuvant therapy pathologic tumor categorization (ypT): (ypTx, ypT0, ypTis, ypT1mi, ypT1a, ypT1b, ypT1c, ypT2, ypT3, ypT4a, ypT4b, ypT4c). * Pathological Lymph Nodes - post-neoadjuvant therapy pathologic node categorization (ypN): (ypNX, ypN0, ypN0(i+), ypN0(mol+), ypN1, ypN1mi, ypN1a, ypN1b, ypN1c, ypN2, ypN2a, ypN2b, ypN3, ypN3a, ypN3b, ypN3c). * ypT0 / ypN0 indicates no evidence of disease and the progressive grades indicate increasing size of tumor and increasing area of lymph node involvement respectively and ypTx/ypNX indicates non-measurable disease.
Time frame: At Cycle 6 Day 18 (approximately 5.5 months), each cycle is 28 days
Pathological Complete Response(pCR) Rate at the Time of Surgical Resection
pCR is defined as no invasive cancer in the breast and sampled axillary lymph nodes following completion of neoadjuvant systemic therapy (ie, Pathologic Tumor - ypT = ypT0 or ypTis, and Pathologic Lymph Nodes - ypN = ypN0 in the current American Joint Committee on Cancer (AJCC) staging system). pCR rate is the percentage of participants with pCR.
Time frame: At Cycle 6 Day 18 (approximately 5.5 months), each cycle is 28 days
Number of Participants With Modified Preoperative Endocrine Prognostic Index (mPEPI) Score of 0 at the Time of Surgical Resection
Modified Pre-operative Endocrine Prognostic Index (mPEPI) score is an investigational prognostic tool used to predict the risk of breast cancer recurrence. It will be derived from factors assigned a numerical score following Neoadjuvant endocrine treatment (NET). The factors include pathologic tumor size, and lymph node status and Ki67 expression in the surgical specimen. Total mPEPI score (mPEPI\_T) per participant is the sum of mPEPI score of each factor. mPEPI score of 0 indicates Pathological tumor size T1-T2, no lymph nodes and Ki67 level of 0%-2.7%, 1 indicates: Ki67 level \>2.7%-7.3%, 2 indicates Ki67 level \>19.7%-53.1% and 3 indicates: tumor sizeT3-T4, presence of lymph nodes and Ki67 level \>53.1%.
Time frame: At Cycle 6 Day 18 (approximately 5.5 months), each cycle is 28 days
Breast Conserving Surgery (BCS) Rate
Breast conserving surgery (BCS) Rate is the percentage of participants received breast conserving surgery.
Time frame: At Cycle 6 (from Day 141 to Day 168), each cycle is 28 days
Radiographic Response Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST) in Primary Tumor During Cycle 6
The number of participants with Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD), Not Evaluable (NE) per mRECIST calculated. CR = disappearance of all target lesions, PR is \>=30% decrease in sum of diameters of target lesions, progressive disease (PD) is \>=20% increase in sum of diameters of target lesions, stable disease (SD) is \<30% decrease or \<20% increase in sum of diameters of target lesions.
Time frame: At Cycle 6 (from Day 141 to Day 168), each cycle is 28 days
Percentage Change From Baseline at Cycle 6 Day 1 in Caliper Measurement of the Primary Tumor
The percentage change from the baseline of the primary breast tumor size in physical exam calculated in caliper measurement. Caliper-based response is the maximum percentage decrease or minimum percentage increase if there is no decrease per participant.
Time frame: Baseline (Day 1) and Cycle 6 Day 1 (At Day 141), each cycle is 28 days
| Milestone | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole |
|---|---|---|
| Started | 102 | 50 |
| Treated | 101 | 48 |
| Completed | 94 | 41 |
| Not completed | 8 | 9 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Other: miscellaneous | 3 | 6 |
Tumor biopsy Ki-67 expression (% of tumor cells that are positive for Ki-67) at baseline and Cycle 1 Day 15 (C1D15) was collected. Ki-67 expression was assessed by immunohistochemical staining in a central laboratory. The log-transformed Ki-67 after approximately 2 weeks of treatment as a percentage of the baseline value, ie, the ratio between the Ki-67 measurements obtained from C1D15 visit and baseline was modelled using a generalized linear model (GLM) with both stratification factors (ie, baseline Ki-67 score and the tumor size) and treatment as co-variates. The treatment effects were back transformed into geometric means and their Confidence Intervals. The percent change, in other words, relative reduction, of Ki-67 after 2 weeks of treatment is reported as the complement of the ratio between the Ki-67 measurement from C1D15 and baseline, that is 100% × (1 - geometric mean ratio between Ki-67 at C1D15 and Ki-67 at baseline).
| Percent reduction | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole |
|---|---|---|
| Percent Reduction in Ki-67 Expression From Baseline to Day 15 in Tumor Biopsies | 71.4 (60.6 to 79.3) | 72.9 (57.8 to 82.6) |
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE is an AE that emerges or worsens on/after the first dose of ARV-471/Anastrozole to 30 days after the last administration of the study intervention (ie, study drug treatment or surgical resection, whichever occurs last).
| Participants | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole |
|---|---|---|
| TEAEs | 82 | 37 |
| Serious TEAEs | 4 | 5 |
| TEAEs leading to study drug discontinuation | 3 | 4 |
Local pathological assessment of the tissue from surgical resection (performed after approximately 5.5 months of treatment), at minimum, included pathologic stage (ypT and ypN stage) as described in the Laboratory Manual. Participants were analysed based on the current American Joint Committee on Cancer (AJCC) staging system as follows: * Pathologic Tumor - post-neoadjuvant therapy pathologic tumor categorization (ypT): (ypTx, ypT0, ypTis, ypT1mi, ypT1a, ypT1b, ypT1c, ypT2, ypT3, ypT4a, ypT4b, ypT4c). * Pathological Lymph Nodes - post-neoadjuvant therapy pathologic node categorization (ypN): (ypNX, ypN0, ypN0(i+), ypN0(mol+), ypN1, ypN1mi, ypN1a, ypN1b, ypN1c, ypN2, ypN2a, ypN2b, ypN3, ypN3a, ypN3b, ypN3c). * ypT0 / ypN0 indicates no evidence of disease and the progressive grades indicate increasing size of tumor and increasing area of lymph node involvement respectively and ypTx/ypNX indicates non-measurable disease.
| Participants | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole |
|---|---|---|
| Pathologic Tumor ypTx | 0 | 0 |
| Pathologic Tumor ypT0 | 1 | 0 |
| Pathologic Tumor ypTis | 1 | 0 |
| Pathologic Tumor ypT1mi | 1 | 0 |
| Pathologic Tumor ypT1a | 6 | 1 |
| Pathologic Tumor ypT1b | 7 | 2 |
| Pathologic Tumor ypT1c | 36 | 14 |
| Pathologic Tumor ypT2 | 33 | 21 |
| Pathologic Tumor ypT3 | 4 | 2 |
| Pathologic Tumor ypT4a | 1 | 0 |
| Pathologic Tumor ypT4b | 0 | 0 |
| Pathologic Tumor ypT4c | 0 | 0 |
| Pathologic Tumor Not Evaluable | 12 | 10 |
| Pathological Lymph Nodes ypNX | 0 | 0 |
| Pathological Lymph Nodes ypN0 | 51 | 20 |
| Pathological Lymph Nodes ypN0(i+) | 0 | 0 |
| Pathological Lymph Nodes ypN1 | 5 | 4 |
| Pathological Lymph Nodes ypN0(mol+) | 0 | 0 |
| Pathological Lymph Nodes ypN1mi | 4 | 3 |
| Pathological Lymph Nodes ypN1a | 21 | 6 |
| Pathological Lymph Nodes ypN1b | 0 | 0 |
| Pathological Lymph Nodes ypN1c | 1 | 0 |
| Pathological Lymph Nodes ypN2 | 2 | 2 |
| Pathological Lymph Nodes ypN2a | 3 | 4 |
| Pathological Lymph Nodes ypN2b | 0 | 0 |
| Pathological Lymph Nodes ypN3 | 0 | 0 |
| Pathological Lymph Nodes ypN3a | 3 | 1 |
| Pathological Lymph Nodes ypN3b | 0 | 0 |
| Pathological Lymph Nodes ypN3c | 0 | 0 |
| Pathological Lymph Nodes Not evaluable | 12 | 10 |
pCR is defined as no invasive cancer in the breast and sampled axillary lymph nodes following completion of neoadjuvant systemic therapy (ie, Pathologic Tumor - ypT = ypT0 or ypTis, and Pathologic Lymph Nodes - ypN = ypN0 in the current American Joint Committee on Cancer (AJCC) staging system). pCR rate is the percentage of participants with pCR.
| percentage of participants | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole |
|---|---|---|
| Pathological Complete Response(pCR) Rate at the Time of Surgical Resection | 1 | 0 |
Modified Pre-operative Endocrine Prognostic Index (mPEPI) score is an investigational prognostic tool used to predict the risk of breast cancer recurrence. It will be derived from factors assigned a numerical score following Neoadjuvant endocrine treatment (NET). The factors include pathologic tumor size, and lymph node status and Ki67 expression in the surgical specimen. Total mPEPI score (mPEPI\_T) per participant is the sum of mPEPI score of each factor. mPEPI score of 0 indicates Pathological tumor size T1-T2, no lymph nodes and Ki67 level of 0%-2.7%, 1 indicates: Ki67 level \>2.7%-7.3%, 2 indicates Ki67 level \>19.7%-53.1% and 3 indicates: tumor sizeT3-T4, presence of lymph nodes and Ki67 level \>53.1%.
| Participants | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole |
|---|---|---|
| Number of Participants With Modified Preoperative Endocrine Prognostic Index (mPEPI) Score of 0 at the Time of Surgical Resection | 21 | 10 |
Breast conserving surgery (BCS) Rate is the percentage of participants received breast conserving surgery.
| Percentage of participants | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole |
|---|---|---|
| Breast Conserving Surgery (BCS) Rate | 69.6 (60.1 to 77.7) | 54.0 (40.4 to 67.0) |
The number of participants with Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD), Not Evaluable (NE) per mRECIST calculated. CR = disappearance of all target lesions, PR is \>=30% decrease in sum of diameters of target lesions, progressive disease (PD) is \>=20% increase in sum of diameters of target lesions, stable disease (SD) is \<30% decrease or \<20% increase in sum of diameters of target lesions.
| Participants | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole |
|---|---|---|
| CR | 5 | 4 |
| PR | 37 | 17 |
| Stable Disease | 38 | 16 |
| Progressive disease | 3 | 1 |
| NE | 19 | 12 |
The percentage change from the baseline of the primary breast tumor size in physical exam calculated in caliper measurement. Caliper-based response is the maximum percentage decrease or minimum percentage increase if there is no decrease per participant.
| Percent change | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole |
|---|---|---|
| Percentage Change From Baseline at Cycle 6 Day 1 in Caliper Measurement of the Primary Tumor | -32.35 ± 23.739 | -42.88 ± 18.041 |
Collected over Adverse Events: From first study drug administration up to approximately 6.5 months. All-cause mortality: From randomization up to approximately 6.5 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: ARV-471 (Experimental) | 0/102 (0%) | 4/101 (4%) | 72/101 (71.3%) |
| Arm B: Anastrozole | 0/50 (0%) | 5/48 (10.4%) | 32/48 (66.7%) |
| Event | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole |
|---|---|---|
| Angina pectorisCardiac disorders | 0/101 | 1/48 |
| Cardiac arrestCardiac disorders | 0/101 | 1/48 |
| Postoperative wound infectionInfections and infestations | 0/101 | 1/48 |
| Post procedural haematomaInjury, poisoning and procedural complications | 0/101 | 1/48 |
| EncephalopathyNervous system disorders | 0/101 | 1/48 |
| BacteraemiaInfections and infestations | 1/101 | 0/48 |
| COVID-19Infections and infestations | 1/101 | 0/48 |
| Post procedural infectionInfections and infestations | 1/101 | 0/48 |
| PyelonephritisInfections and infestations | 1/101 | 0/48 |
| AtaxiaNervous system disorders | 1/101 | 0/48 |
| Event | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 14/101 | 15/48 |
| Hot flushVascular disorders | 25/101 | 10/48 |
| AstheniaGeneral disorders | 21/101 | 5/48 |
| ConstipationGastrointestinal disorders | 16/101 | 3/48 |
| NauseaGastrointestinal disorders | 15/101 | 1/48 |
| FatigueGeneral disorders | 13/101 | 3/48 |
| HypertensionVascular disorders | 12/101 | 4/48 |
| InsomniaPsychiatric disorders | 9/101 | 1/48 |
| Urinary tract infectionInfections and infestations | 8/101 | 1/48 |
| Decreased appetiteMetabolism and nutrition disorders | 8/101 | 0/48 |
Full Analysis Set (FAS) included all the enrolled participants who were randomized.
| Age, Continuous(years) | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole | Total |
|---|---|---|---|
| Mean | 67.4 ± 9.23 | 66.8 ± 8.31 | 67.2 ± 8.91 |
| Sex: Female, Male(Participants) | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole | Total |
|---|---|---|---|
| Female | 102 | 50 | 152 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole | Total |
|---|---|---|---|
| Hispanic or Latino | 38 | 23 | 61 |
| Not Hispanic or Latino | 59 | 25 | 84 |
| Unknown or Not Reported | 5 | 2 | 7 |
| Race/Ethnicity, Customized(Participants) | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 |
| White | 98 | 46 | 144 |
| Other | 0 | 1 | 1 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Percentage of Tumor Cells Positive for Ki -67(Percentage of tumor cells with Ki67) | Arm A: ARV-471 (Experimental) | Arm B: Anastrozole | Total |
|---|---|---|---|
| Mean | 20.6 ± 14.01 | 20.1 ± 12.25 | 20.4 ± 13.42 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2023 to primary completion in Jul 2024, 16 months.
Results were first posted in Aug 2025, 1 year 1 month after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 16 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vepdegestrant
Arvinas Inc.